Revolutionizing the Practice of Medicine Through Rapid (< 1h) DNA-based Diagnostics

Clin Invest Med. 2008 Oct 1;31(5):E265-71. doi: 10.25011/cim.v31i5.4873.


Twenty years ago, I dreamed of using DNA detection for speeding the microbiological identification of microorganisms from two days to less than one hour. This dream is slowly becoming a reality as we were the first to develop and put on the market real-time PCR assays, approved by the United States Food and Drug Administration and Health Canada, for the detection of several pathogens including Group B streptococci, methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and Clostridium difficile. Since 2000, my team and I have been interested to bring this laboratory revolution to the bedside, by developing a microfluidic centripetal device, a compact disc-like platform that, instead of reading music, reads DNA. This futuristic approach to the management of infectious diseases at point-of-care will undoubtedly necessitate a 'change in culture without culture'.

Publication types

  • Lecture
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA, Bacterial / genetics*
  • Drug Resistance, Bacterial / genetics
  • Gram-Positive Bacteria / genetics*
  • Gram-Positive Bacterial Infections / diagnosis*
  • Gram-Positive Bacterial Infections / genetics
  • Humans
  • Molecular Diagnostic Techniques / instrumentation*
  • Molecular Diagnostic Techniques / methods*
  • Molecular Diagnostic Techniques / trends
  • Polymerase Chain Reaction / instrumentation*
  • Polymerase Chain Reaction / methods*
  • Polymerase Chain Reaction / trends
  • Time Factors


  • DNA, Bacterial